HHGA
BMRN icon

Halbert Hargrove Global Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46 Buy
+1
New +$55 ﹤0.01% 727
2025
Q2 		– Sell
-7
Closed -$514 – 354
2025
Q1 		$514 Buy
+7
New +$471 ﹤0.01% 496

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Halbert Hargrove Global Advisors's BMRN Position: Q2 2026 in Review

Halbert Hargrove Global Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 1 share worth $46. The stake represents ﹤0.01% of the portfolio and ranks #727 among its holdings. This is a return to the name: Halbert Hargrove Global Advisors previously reported a position in BMRN as recently as Q1 2025.

Halbert Hargrove Global Advisors first reported a position in BMRN in Q1 2025 and has held it in 2 quarters since. The position peaked at $514 in Q1 2025. 108 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Halbert Hargrove Global Advisors held 1 share of BioMarin Pharmaceuticals worth $46 as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Halbert Hargrove Global Advisors position in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Halbert Hargrove Global Advisors's portfolio in Q2 2026, its #727 holding.
  • Halbert Hargrove Global Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • Halbert Hargrove Global Advisors's BioMarin Pharmaceuticals position peaked at $514 in Q1 2025.
  • 108 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Halbert Hargrove Global Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.